Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Possible ameliorative effects of pentoxifylline on cisplatin-induced ototoxicity in rats: a study with hearing test, light, and scanning electron microscopy

View through CrossRef
Cisplatin is an antineoplastic drug widely used to treat various types of cancer. Ototoxicity is still cisplatin’s most critical side-effect. Some patients may experience dose limitations due to hearing loss. Pentoxifylline (PX) exhibits powerful antioxidant, anti-inflammatory, and immune-regulatory effects. Our study was designed to investigate the protective effects of pentoxifylline on cisplatin-induced ototoxicity. Forty adult male healthy Sprague-Dawley rats were used through the entire experiment. Four groups of animals were categorized: Group I (control group); Group II (PX group) received 25 mg/kg/day of oral PX by gavage for 8 consecutive days; Group III (Cisplatin group) received cisplatin single intraperitoneal dose of 10 mg/kg; Group IV (PX + Cisplatin group) received 25 mg/kg/day of oral PX by gavage for 8 successive days and a single intraperitoneal dose of 10 mg/kg cisplatin at the 4th day. First and 9th-day Distortiondistortion-product otoacoustic emissions (DPOAE) tests were conducted. An intracardiac blood sample was collected for total antioxidant capacity (TAC) measurement, and the cochleae of rats were examined histopathologically. A significant reduction in serum TAC value was detected in the cisplatin group, while PX treatment significantly reduced TAC. Cisplatin decreased the DPOAE amplitudes in rats; conversely, the PX+cisplatin group showed a significant increase at all frequencies. Upon histopathological examination, the Ciplastin group revealed perturbation of the normal architecture of the organ of Corti, increased collagen deposition and marked expression of caspase-3, while the PX+cisplatin group revealed preserved architecture of the organ of Corti, minimal collagen deposition and downregulation of Caspase-3 expression. As evidenced by our findings and results from DPOAE results, biochemical findings, histological and ultrastructural analyses, PX significantly protects rats against ototoxicity caused by cisplatin.
Title: Possible ameliorative effects of pentoxifylline on cisplatin-induced ototoxicity in rats: a study with hearing test, light, and scanning electron microscopy
Description:
Cisplatin is an antineoplastic drug widely used to treat various types of cancer.
Ototoxicity is still cisplatin’s most critical side-effect.
Some patients may experience dose limitations due to hearing loss.
Pentoxifylline (PX) exhibits powerful antioxidant, anti-inflammatory, and immune-regulatory effects.
Our study was designed to investigate the protective effects of pentoxifylline on cisplatin-induced ototoxicity.
Forty adult male healthy Sprague-Dawley rats were used through the entire experiment.
Four groups of animals were categorized: Group I (control group); Group II (PX group) received 25 mg/kg/day of oral PX by gavage for 8 consecutive days; Group III (Cisplatin group) received cisplatin single intraperitoneal dose of 10 mg/kg; Group IV (PX + Cisplatin group) received 25 mg/kg/day of oral PX by gavage for 8 successive days and a single intraperitoneal dose of 10 mg/kg cisplatin at the 4th day.
First and 9th-day Distortiondistortion-product otoacoustic emissions (DPOAE) tests were conducted.
An intracardiac blood sample was collected for total antioxidant capacity (TAC) measurement, and the cochleae of rats were examined histopathologically.
A significant reduction in serum TAC value was detected in the cisplatin group, while PX treatment significantly reduced TAC.
Cisplatin decreased the DPOAE amplitudes in rats; conversely, the PX+cisplatin group showed a significant increase at all frequencies.
Upon histopathological examination, the Ciplastin group revealed perturbation of the normal architecture of the organ of Corti, increased collagen deposition and marked expression of caspase-3, while the PX+cisplatin group revealed preserved architecture of the organ of Corti, minimal collagen deposition and downregulation of Caspase-3 expression.
As evidenced by our findings and results from DPOAE results, biochemical findings, histological and ultrastructural analyses, PX significantly protects rats against ototoxicity caused by cisplatin.

Related Results

Predictive model for aminoglycoside induced ototoxicity
Predictive model for aminoglycoside induced ototoxicity
BackgroundIrreversible hearing loss is a well-known adverse effect of aminoglycosides, however, inability to accurately predict ototoxicity is a major limitation in clinical care. ...
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
RAD51C is a RAD51 paralog protein that mediates RAD51 filament formation on single-stranded DNA (ssDNA) in a canonical homologous recombination (HR) pathway. This step is vital for...
Intratympanic Dexamethasone to Prevent Cisplatin Ototoxicity
Intratympanic Dexamethasone to Prevent Cisplatin Ototoxicity
ObjectiveTo determine whether intratympanic administration of dexamethasone reduces ototoxicity from systemic cisplatin.Study DesignProspective animal study.SettingCisplatin chemot...
Possible Protective Effect of Sertraline against Cisplatin‐Induced Ototoxicity: An Experimental Study
Possible Protective Effect of Sertraline against Cisplatin‐Induced Ototoxicity: An Experimental Study
Background/Objective. Cisplatin is a widely used chemotherapeutic agent, but its ototoxicity side effect can occur in the majority of patients. Lots of agents were tried to prevent...
Extended-Interval Aminoglycoside Administration for Children: A Meta-analysis
Extended-Interval Aminoglycoside Administration for Children: A Meta-analysis
Background. There has been a long-standing debate regarding whether aminoglycosides should be administered on a multiple daily dosing (MDD) or once-daily dosing (ODD) schedule. Sev...
The effects of recombinant klotho in cisplatin‐induced ovarian failure in mice
The effects of recombinant klotho in cisplatin‐induced ovarian failure in mice
AbstractAimTo investigate whether recombinant klotho given concomitantly with cisplatin is effective in preventing cisplatin‐induced ovarian damage.MethodsThirty‐two adult female m...
Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies
Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies
Cisplatin is a highly effective chemotherapeutic agent that is widely used to treat solid organ malignancies. However, serious side effects have been associated with its use, such ...

Back to Top